Comparison of the Cost-Effectiveness of Absolute Risk with Treatment According to Either Blood Pressure or Lipid Targets Alone in Addition to Population-based Strategies, Selected WHO Regions | | | Incremental cost-effectiveness ratio (cost/DALY saved)a |
| Region | Strategy | Risk (percent) | International $ | US$ |
| Africa E | Prevention (SL and/or HE) | | Dominatedb | |
| Targeted risk factorsc | | Dominatedb | |
| Absolute riskc (TRI) | 35 | 138 | 42 |
| | 25 | 778 | 295 |
| | 15 | 1,445 | 639 |
| Latin America and the | Prevention (SL) | | 127 | 65 |
| Caribbean B | Prevention (SL + HE) | | 145 | 74 |
| Targeted risk factorsc | | Dominatedb | |
| Absolute riskd (TRI + SL + HE) | 35 | 286 | 178 |
| | 25 | 1,598 | 1,058 |
| | 15 | 2,391 | 1,664 |
| | 5 | 4,319 | 3,075 |
| Southeast Asia B | Prevention (SL) | | 70 | 18 |
| Prevention (SL + HE) | | 127 | 32 |
| Targeted risk factorsc | | Dominatedb | |
| Absolute riskd (TRI + SL + HE) | 35 | 301 | 133 |
| | 25 | 1,197 | 578 |
| | 15 | 2,094 | 1,120 |
| | 5 | 3,952 | 2,233 |
| Western Pacific B | Prevention (SL) | | 97 | 18 |
| Targeted risk factorsc | | Dominatedb | |
| Absolute riskd (TRI + SL + HE) | 35 | 1,124 | 423 |
| | 25 | 1,278 | 564 |
| | 15 | 2,092 | 1,042 |
| | 5 | 4,028 | 2,135 |
Source: Murray and others 2003.
B = low child mortality and low adult mortality; E = high child mortality and very high adult mortality; HE = health education through the mass media to reduce cholesterol; SL = legislation to decrease the salt content of processed foods, including appropriate labeling and enforcement; TRI = treatment with aspirin, beta-blockers, and a statin.
a. Costs of prevention and nondrug costs for treatment according to absolute risk are converted at an estimated regional average ratio of exchange rate to purchasing-power parity rate; drug costs are not converted, assuming drugs to be imported at world prices. The share of drug costs in total treatment cost, as a function of risk, is taken from the estimates for India in table 45.6 and assumed to be the same for all regions.
b. Dominated strategies were both less effective and more costly than comparator strategies.
c. Treating SBP greater than 140 mmHg or 160 mmHg or total cholesterol greater than 5.7 mmol/l or 6.2 mmol/l (220 or 240 mg/dlL).
d. Risk refers to 10-year risk of CVD greater than or equal to the number listed.